research use only

Brimonidine Adrenergic Receptor agonist

Name: Brimonidine
Brand: Selleck Chemicals
SKU: S9508
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S9508

Brimonidine (Bromoxidine, UK 1430) is an alpha adrenergic receptor agonist (primarily alpha-2) and is used for the treatment of open-angle glaucoma or ocular hypertension to lower intraocular pressure.

Chemical Structure

Molecular Weight: 292.13

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	AChR 5-HT Receptor COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR MAO Beta Amyloid NMDAR iGluR P2 Receptor Trk receptor Serotonin Transporter Notch Norepinephrine Cannabinoid Receptor P-gp CaMK Opioid Receptor BACE Sigma Receptor FAAH Neurokinin Receptor OX Receptor CGRP Receptor CCK receptor
Related Products	Zenidolol (ICI-118551) Hydrochloride Yohimbine HCl L755507 Atipamezole Higenamine hydrochloride Fenoterol hydrobromide Medetomidine HCl Rauwolscine hydrochloride Deoxycorticosterone acetate Detomidine HCl Naftopidil Demethyl-Coclaurine Scopine Buflomedil HCl Labetalone hydrochloride DL-Adrenaline Landiolol hydrochloride Noradrenaline bitartrate monohydrate Adrenergic α 1A Receptor/ADRA1A Antibody [C20D16] Alprenolol hydrochloride Fenoterol Clorprenaline HCl Moxisylyte hydrochloride L-765314 Fargesin Urapidil Isoprenaline Naftopidil DiHCl Tetryzoline Xylometazoline HCl

Chemical Information, Storage & Stability

Molecular Weight	292.13	Formula	C₁₁H₁₀BrN₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	59803-98-4	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Bromoxidine, UK 14304			Smiles	C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br

Solubility

In vitro
Batch:

DMSO : 29 mg/mL (99.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05006898	Completed	Presbyopia	Optall Vision	June 1 2020	Phase 1
NCT03825081	Unknown status	Presbyopia\|Pseudophakia	Massachusetts Eye and Ear Infirmary	January 21 2019	Early Phase 1
NCT02967614	Completed	Glaucoma\|Eye Diseases\|Ocular Hypertension	Kukje Pharma	December 2016	Phase 1
NCT02761174	Completed	Telangiectasias	Merete Haedersdal\|Skinperium Christine Dierickx\|Ellipse A/S Agern Allé 11 2970 Hørsholm\|Bispebjerg Hospital	March 13 2016	Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):